Shasqi Awarded a Second NCI Grant of $1.9M to Accelerate the Development of SQ3370

SAN FRANCISCO--(BUSINESS WIRE)--Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC™) Platform, announced today that it has been awarded a second ‘Direct to Phase 2’ Small Business Innovation Research (SBIR) grant from the National Cancer Institute (NCI). The $1.9 million...

Click to view original post